يعرض 1 - 10 نتائج من 35 نتيجة بحث عن '"Tim Harrison"', وقت الاستعلام: 0.76s تنقيح النتائج
  1. 1

    المساهمون: Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

    المصدر: Allergy
    Allergy, 2022, 77 (1), pp.150-161. ⟨10.1111/all.14902⟩

  2. 2

    المصدر: The Lancet. Respiratory Medicine
    Heaney, L G, Busby, J, Hanratty, C E, Djukanovic, R, Woodcock, A, Walker, S M, Hardman, T C, Arron, J R, Choy, D F, Bradding, P, Brightling, C E, Chaudhuri, R, Cowan, D C, Mansur, A H, Fowler, S J, Niven, R M, Howarth, P H, Lordan, J L, Menzies-Gow, A, Harrison, T W, Robinson, D S, Holweg, C T J, Matthews, J G & Pavord, I D 2020, ' Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 1, pp. 57-68 . https://doi.org/10.1016/S2213-2600Test(20)30397-0
    Investigators for the MRC Refractory Asthma Stratification Programme 2020, ' Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma : a multicentre, single-blind, parallel group, randomised controlled trial ', The Lancet. Respiratory medicine, vol. 9, no. 1, pp. 57-68 . https://doi.org/10.1016/S2213-2600Test(20)30397-0

    وصف الملف: application/pdf; PDF; text

  3. 3
  4. 4

    المصدر: The Lancet Respiratory Medicine
    Monk, P D, Marsden, R J, Tear, V J, Brookes, J, Batten, T N, Mankowski, M, Gabbay, F J, Davies, D E, Holgate, S T, Ho, L-P, Clark, T, Djukanovic, R, Wilkinson, T M A & Group, I I B COVID S 2021, ' Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial ', The Lancet. Respiratory medicine, vol. 9, no. 2, pp. 196—206 . https://doi.org/10.1016/s2213-2600Test(20)30511-7

    وصف الملف: text

  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    المصدر: Protocol 012 Investigators 2020, ' Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600Test(19)30471-0

    وصف الملف: application/pdf

  10. 10